Fig 2. Reactivation of latent HIV-1 with combinations of celastrol and well-characterized LRAs.

Jurkat 2D10 cells were treated with 0.4 μM celastrol plus 0.2 μM JQ1, 400 nM vorinostat, 20 nM romidepsin, or 0.2 ng/ml bryostatin. Reactivation of latent HIV-1 was quantified by flow cytometry analysis of eGFP expression at 24 hours post-treatment. Cell viability was quantified by Vi-Cell (Beckman Coulter). Bliss synergy scores for 0.4μM celastrol plus JQ1 (0.2 μM), Bryostatin (0.2 ng/ml), Vorinostat (0.4 μM), or Romidepsin (20 nM) were 13.2, 8.4, 19.9, and 13.8, respectively. The data presented in Fig 2 are representative of more than three biological replicate experiments.